Corporate Update – 15 May 2026
BioNTech SE convened its virtual Annual General Meeting (AGM) on 15 May 2026, with the majority of shareholders participating through the online platform. All motions submitted by management were approved, confirming the company’s strategic direction to intensify focus on late‑stage oncology development while continuing early‑stage research aimed at long‑term innovation.
Board Composition and Governance
Shareholders voted to increase the supervisory board from six to eight members, adding:
| New Member | Credentials | Focus |
|---|---|---|
| Prof. Dr. Iris Löw‑Friedrich | Extensive experience in clinical development, science, and commercial strategy | Strengthening scientific oversight and commercial planning |
| Dr. Susanne Schaffert (also on the board of Merck KGaA) | Expertise in oncology, product launch, and organisational leadership | Enhancing commercial execution and market positioning |
These appointments are intended to broaden the board’s knowledge base across both scientific and commercial domains, thereby supporting more informed governance decisions.
The AGM also reaffirmed the terms of existing board members Helmut Jeggle, Prof. Dr. Anja Morawietz, and Prof. Dr. Rudolf Staudigl. Following the meeting, Helmut Jeggle was elected chairman of the board, ensuring continuity in governance and strategic oversight.
Strategic Highlights
Speeches delivered by CEO Prof. Dr. Ugur Sahin and CFO Ramón Zapata underscored the company’s commitment to innovative cancer therapies. Key points included:
- Late‑stage Oncology Pipeline: BioNTech is accelerating development of pan‑tumor and synergistic treatments, targeting both early and advanced disease stages. Ongoing trials focus on safety, efficacy, and biomarker‑driven patient selection.
- Collaborations: The company maintains partnerships with leading entities such as Bristol Myers Squibb, Genentech, and Pfizer. These collaborations aim to leverage complementary expertise in immuno‑oncology and drug delivery technologies.
- Regulatory Pathways: BioNTech is actively engaging with regulatory authorities to expedite approvals for its oncology candidates, employing adaptive trial designs and real‑world evidence to support benefit‑risk assessments.
Practical Implications for Patient Care
The strategic emphasis on pan‑tumor therapies suggests a potential for broader patient eligibility and improved outcomes across multiple cancer types. Continued investment in early‑stage research may yield novel modalities with enhanced safety profiles and reduced toxicity, addressing unmet clinical needs. The strengthened supervisory board is expected to facilitate more rapid translation of scientific discoveries into marketable therapies, ultimately benefiting healthcare systems by expanding therapeutic options and optimizing resource utilization.
Documentation
All voting results and presentation materials from the AGM are publicly available on BioNTech’s investor relations website. No additional information beyond the company’s official disclosures is included in this summary.
